WASHINGTON (Reuters) -U.S. Food and Drug Administration (FDA) Principal Deputy Commissioner Dr. Janet Woodcock, who led the regulator during the height of the COVID-19 pandemic as acting chief, plans to retire early next year, the agency said on Thursday. Woodcock, 75, is an FDA veteran who twice led its pharmaceutical division for at least a decade in each instance. There she reshaped the drug approval process, relaxing the criteria needed for certain drugs to reach the market.
WASHINGTON (BUSINESS WIRE) Greenleaf Health, Inc. (Greenleaf), a leading Food and Drug Administration (FDA) regulatory consulting firm, today announces that Wilson Bryan, M.D., has joined as Executive Vice President, Drug and Biological Products. Wilson served as Director of the Office of Tissues and Advanced Ther.
LIVE 8:45 AM ET: Science Policy After the COVID-19 Crisis — an AEI Event theepochtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theepochtimes.com Daily Mail and Mail on Sunday newspapers.
US Needs Plan to Coordinate Research Before Next Pandemic, Officials Say theepochtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theepochtimes.com Daily Mail and Mail on Sunday newspapers.